News and Views

The Official Blog of WhaleWisdom.com

HCA Healthcare, Inc. (HCA) experienced stock fluctuation over the past year but has seen growth in recent months. HCA’s stock underperformed the S&P 500, falling by approximately 21% year-to-date compared to the S&P’s loss of about 10%. However, hedge funds were buying, and the health care services company was added to the WhaleWisdom Whale 100 Index on August 16, 2022.

HCA Healthcare owns and operates healthcare facilities across the United States and the United Kingdom. Its medical facilities include a range of hospitals, medical clinics, and ambulatory care sites, offering inpatient care, intensive care, cardiac care, diagnostic, and emergency services. HCA Healthcare’s potential for growth depends upon patient volume and revenue collected from patients and third-party insurance payers. The Coronavirus pandemic has stressed HCA Healthcare and the healthcare industry, contributing to surges in some areas of business, declines in others, and rising medical costs.

(WhaleWisdom)

Hedge Funds Are Buying

HCA Healthcare saw a mixed response from hedge funds and institutions in the second quarter of 2022. Hedge Funds added to their portfolios in the second quarter, and the aggregate 13F shares increased to approximately 69.6 million from 62.7 million, a gain of about 11.0%. Overall, 31 hedge funds created new positions, 90 added, 39 exited, and 64 reduced their stakes. Institutions adjusted their portfolios, lowering their holdings by about 4.8% to 187.1 million shares.

(WhaleWisdom)

Positive Estimates

Analysts expect to see revenue rise through 2023 with year-over-year growth that could increase revenue to $63.4 billion by December 2023. Analysts are also optimistic about earnings and predict earnings per share of $17.26 by December 2022 and $19.05 by December 2023. The company’s 13F metrics show a span of upward mobility between 2012 and 2022, demonstrating HCA Healthcare’s investment potential.

(WhaleWisdom)

Analysts Raise Price Targets

Analyst John Ransom of Raymond James & Associates raised the firm’s price target on HCA Healthcare to $250 from $230 and kept an Outperform rating on shares following an analysis of second quarter results and labor trends. SVB Securities analyst Whit Mayo held an Outperform rating on HCA Healthcare’s shares and raised the firm’s price target to $259 from $240. Ann Hynes of Mizuho Securities Co. maintained a Buy rating on shares and raised their firm’s price target to $230 from $210.

Favorable Outlook Beyond 2022

HCA Healthcare’s growth history has been strong, and hedge funds are bullish on the stock. Past trends and analysts’ predictions for increased earnings bring optimism for the future. HCA Healthcare’s facilities and services will likely see continued demand, and investors may see the stock as an excellent long-term investment.

S&P Global Inc. (SPGI) has navigated volatility amid rising inflation rates and geopolitical factors affecting the market over the past year. Ultimately, the stock has closely shadowed the S&P 500’s performance and recently made its mark on the WhaleWisdom Heatmap with a rank of four. While S&P Global saw improvement in recent months, overall, its price has declined about 20% year-to-date compared to the S&P 500’s loss of approximately 10% as of September 15, 2022.

S&P Global, formerly known as McGraw-Hill Inc., is a corporation focused on financial information and analytics. It is a parent company with six key business lines: Commodity Insights, Dow Jones Indices, Engineering Solutions, S&P Global Market Intelligence, and S&P Global Ratings. S&P Global and its subsidiaries collectively provide independent credit ratings, analytics, benchmarks, and workflow solutions for various worldwide markets, deriving much of its revenue from recurring subscription fees. Earlier this year, S&P Global merged with IHS Markit Ltd. with a focus on combining their complementary assets and technological capabilities to serve customers better.

Hedge Funds and Institutions Sell

Hedge Funds adjusted their portfolios in the second quarter, and the aggregate 13F shares held decreased to approximately $59.6 million from $67.5 million, a slide of about 11.8%. Overall, 28 hedge funds created new positions, 117 added, 48 exited, and 126 reduced their holdings. Institutions also sold and lowered their holdings by about 5.7% to $290.9 million.

(WhaleWisdom)

Encouraging Estimates

Analysts anticipate positive revenue momentum, with growth increases that could bring revenue to approximately $13.0 billion by December 2023, up from an estimated $12.0 billion in 2022. Year-over-year estimated increases could also bring earnings to $13.87 per share by December 2023, up from a predicted $11.48 for December 2022. The 13F metrics between 2007 and 2022 show that funds held remain on an upward trajectory despite fluctuations in S&P Global’s stock price.

(WhaleWisdom)

Analysts Increase Ratings

Analysts have become bullish on the stock, raising their price targets and ratings. Analyst Sameer Kalucha of Deutsche Bank raised the firm’s price target on S&P Global to $450 from $435 and kept a Buy rating on shares. Morgan Stanley analyst Toni Kaplan adjusted the firm’s price target to $476 from $460. Kaplan believes that Ratings revenue will increase and maintains an Overweight rating on S&P Global’s shares. RBC Capital Markets initiated coverage of S&P Global with an Outperform rating. Analyst Ashish Sabadra of RBC Capital thought well of the February 2022 acquisition of IHS Markit and set a price target of $476.

Fair Outlook

S&P Global’s performance has shown improvement in recent months, and there are predictions for continued revenue growth. As businesses and governments continue leveraging data analytics and technology to make better decisions, S&P Global’s services will likely see ongoing demand. Analysts’ 2023 earnings estimate for S&P Global is encouraging for investors.

Netflix, Inc. (NFLX) saw a decline in value over the past year, and the stock significantly underperformed the S&P 500. Despite rising on the WhaleWisdom Heatmap to nine, hedge funds have been actively selling shares. Netflix’s stock declined by over 70% as of September 8, 2022, compared to the S&P 500’s less severe loss of around 12%.

Netflix is an entertainment services company that provides streaming content. Netflix offers on-demand subscriptions to allow viewers to see many of their favorite television (TV) shows, movies, and documentaries and play mobile games. The company produces and co-produces Netflix Original content in addition to acquiring rights for film and tv titles from other production studios. Subscribers to the platform may watch content through any device connected to the internet, such as smart TVs, smartphones, and laptop computers. Netflix is one of the largest streaming providers globally, though its origin began with DVD rentals by mail, a service the company continues to offer. While Netflix saw a boost in subscribers at the coronavirus pandemic, it has since seen losses due to various factors, including subscribers closing accounts, ending its operations in Russia, and competing streaming services. The company also continues to lose revenue due to customers’ password sharing, a practice it’s taking action to curb.

Hedge Funds and Institutions Sell

Hedge Funds adjusted their portfolios in the second quarter, and the aggregate 13F shares held decreased to approximately $70.8 million from $73.4 million, a slide of about 3.6%. Overall, 50 hedge funds created new positions, 139 added, 114 exited, and 99 reduced their stakes. Institutions lowered their holdings by about 3.3% to $333.7 million from 345.2 million.

(WhaleWisdom)


Encouraging Multi-year Estimates

Analysts expect to see earnings rise through 2023, with year-over-year increases in growth that could bring earnings to $10.93 per share by December 2023, up from a projected $10.30 for 2022. Revenue predictions are also favorable, with revenue expected to increase to about $34.2 billion by 2023, up from an estimated $31.7 billion. Netflix’s 13F metrics between 2005 and 2022 reflect the company’s fluctuating stock price amid market volatility and recent hits to its subscriber base.

(WhaleWisdom)

Mixed Responses from Analysts

Analyst Andrew Uerkwitz of Jefferies Group LLC lowered the firm’s price target on Netflix to $230 from $243 and kept a Hold rating on shares. Jeffries shared cautious optimism for the next quarter if strategically ad-supported content can help boost subscribers higher and the company can reduce losses from customer password-sharing. Tim Nollen of Macquarie Bank enthusiastically raised the firm’s price target on Netflix to $230 from $170 and upgraded the company to a Neutral rating, noting the company’s long-term potential.

Optimistic Long-term Outlook

After a disappointing start to the year, Netflix is likely to see a rebound, as the long-term trends for the company are favorable. While hedge funds were selling and growth has declined this year, analysts have shared optimistic earnings and revenue estimates for 2022 and 2023. Netflix is working to recover lost subscriber fees and continues to utilize viewership data trends to improve its content and boost revenue. The stock should recover over time as demand for the company’s entertainment services continues.

Qualcomm Inc. (QCOM) continues to face market volatility and a decline in growth, though the company has outperformed the S&P 500. As of September 2, 2022, Qualcomm was down by approximately 10% compared to the S&P 500’s loss of about 12% over the past year. In the second quarter of 2022, the company made the WhaleWisdom Heatmap with a rank of two.

Qualcomm is a multinational corporation that creates semiconductors and software while offering wireless technology services. The company operates through three core segments: Qualcomm CDMA Technologies, Qualcomm Technology Licensing, and Qualcomm Strategic Initiatives. Qualcomm is a leading chipmaker and utilizes mobile chip technology to serve personal computers, Internet of Things, and automotive markets. Qualcomm has made a considerable mark on wireless technology with its patents for mobile communication, such as 5G and CDMA, which align well with its goals to innovate and intelligently connect the world.

(WhaleWisdom)

Hedge Funds Adjust Portfolios

Hedge funds were selling in the second quarter of 2022, and the aggregate 13F shares held decreased approximately 0.9% to about 147.5 million from 148.8 million. Of the hedge funds, 26 created new positions, 204 added, 27 exited, and 130 reduced their stakes. Institutions also sold and decreased their aggregate holdings by about 1.8% to approximately 796.3 million from 810.5 million.

(WhaleWisdom)

Favorable Estimates

Analysts expect to see earnings rise to $12.52 per share by September 2022 and $12.98 by September 2023. Revenue estimates also offer encouragement, with predictions of approximately $46.8 billion in September 2023, up from an estimated $44.2 billion for 2022. The 13F metrics over the past twenty years show that funds remained steady, even as Qualcomm’s stock price fluctuated.

(WhaleWisdom)

Analysts Share Optimistic Price Targets

Analysts’ price targets may vary, but most view Qualcomm as an investment opportunity. Analyst Vijay Rakesh of Mizuho Securities Co. raised the firm’s price target to $175 from $168 and kept a Buy rating on shares. Edward Jones & Co. analyst Logan Purk upgraded Qualcomm’s rating to a Buy from a Hold, noting the opportunity for growth. Gary Mobley of Wells Fargo Securities raised the firm’s price target to $150 from $135, maintaining an Equal Weight rating on Qualcomm’s shares and citing softness in the smartphone market. Analyst T. Michael Walkley of Canaccord Genuity kept a Buy rating on shares and lowered the firm’s price target to $225 from $250. Walkley spoke of Qualcomm’s strong 5G leadership position and the opportunity for long-term solid market growth.

Positive Outlook

Qualcomm’s stock may have lost some ground, but the technology company has shown continued growth. Hedge funds were selling in the second quarter, though earnings and revenue estimates through 2023 look favorable. Bullish investors will take note of Qualcomm’s ability to outperform the market and view the stock as a long-term investment opportunity.

UnitedHealth Group, Inc. (UNH) has made steady gains over the past year, despite a challenging market. Though hedge funds were selling in the second quarter, the company continued to climb the WhaleWisdom Heatmap to a rank of three in the second quarter. UnitedHealth Group has significantly outperformed the S&P 500, rising by approximately 30% compared to the S&P’s loss of about 5% over the past year.

UnitedHealth is an American healthcare and insurance company with two segments: UnitedHealthcare and OptumRx. Its UnitedHealthcare segment offers employers consumer-oriented health benefit plans and services, while the OptumRx business line provides pharmacy services and programs. UnitedHealth is one of the nation’s largest health insurers, offering a variety of health benefit plans and programs with the mission of helping people live healthier lives and improving the health care system’s performance.

(WhaleWisdom)

Hedge Funds Sell Despite Growth

Hedge Funds adjusted their portfolios, and the aggregate 13F shares held decreased to approximately 143.0 million from 150.7 million, a reduction of about 5.1%. Overall, for hedge funds, 29 created new positions, 173 added, 46 exited, and 206 reduced their stakes. Institutions decreased their holdings by about 1.2% to 801.4 million from 810.9 million. The track record of 13F metrics between 2000 and 2022 suggests that UnitedHealth remains on an upward trend.

(WhaleWisdom)

Encouraging Multi-year Estimates

Analysts expect to see positive momentum for revenue, with increases in growth through 2023 that could bring revenue to approximately $349.3 billion by December 2023, up from an estimated $322.2 billion in 2022. Year-over-year estimated increases could also bring earnings to $24.89 per share by December 2023, up from a predicted $21.85 for December 2022. Year-over-year growth is estimated to bring revenue to approximately $38.2 billion by December 2023, up from an estimated $25.8 billion in December 2021.

(WhaleWisdom)

Analysts Raise Price Targets

Analysts are bullish on the stock following strong second-quarter results. Analyst Ann Hynes of Mizuho Securities Co., Ltd. raised the firm’s price target on UnitedHealth to $600 from $550 and kept a Buy rating on shares. Argus Research Co. analyst David Toung also maintained a Buy rating on the stock and raised the firm’s price target to $650 from $580. Kevin Caliendo of UBS Securities kept a Neutral rating on UnitedHealth’s shares and increased the firm’s price target to $570 from $545. Despite United Health management’s outlook, Caliendo’s milder price adjustment speaks to cautiousness given the uncertainty of the Coronavirus pandemic and its future impact on hospitalizations and medical costs. BMO Capital Markets analyst Matt Borsch raised the firm’s price target on UnitedHealth to $610 from $600 following positive Q2 results. Borsch maintained a Market Perform rating on the stock and appeared encouraged by the favorable medical cost trend and not concerned at this time with the potential for increased competition or regulatory scrutiny of managed care organizations.

Favorable Outlook

UnitedHealth has experienced healthy growth over the past year, and analysts’ earnings and revenue growth predictions are optimistic. The company’s health programs and pharmacy services will likely see continued demand, encouraging investors to view UnitedHealth as an investment opportunity.